Background. Control of Clostridium difficile infection (CDI) is an increasingly difficult problem for health care institutions. There are commonly recommended strategies to combat CDI transmission, such as oral vancomycin for CDI treatment, increased hand hygiene with soap and water for health care workers, daily environmental disinfection of infected patient rooms, and contact isolation of diseased patients. However, the efficacy of these strategies, particularly for endemic CDI, has not been well studied. The objective of this research is to develop a valid, agent-based simulation model (ABM) to study C. difficile transmission and control in a midsized hospital. Methods. We develop an ABM of a midsized hospital with agents such as patients, health care workers, and visitors. We model the natural progression of CDI in a patient using a Markov chain and the transmission of CDI through agent and environmental interactions. We derive input parameters from aggregate patient data from the 2007-2010 Wisconsin Hospital Association and published medical
Background. Control of Clostridium difficile infection (CDI) is an increasingly difficult problem for health care institutions. There are commonly recommended strategies to combat CDI transmission, such as oral vancomycin for CDI treatment, increased hand hygiene with soap and water for health care workers, daily environmental disinfection of infected patient rooms, and contact isolation of diseased patients. However, the efficacy of these strategies, particularly for endemic CDI, has not been well studied. The objective of this research is to develop a valid, agent-based simulation model (ABM) to study C. difficile transmission and control in a midsized hospital. Methods. We develop an ABM of a midsized hospital with agents such as patients, health care workers, and visitors. We model the natural progression of CDI in a patient using a Markov chain and the transmission of CDI through agent and environmental interactions. We derive input parameters from aggregate patient data from the 2007-2010 Wisconsin Hospital Association and published medical literature. We define a calibration process, which we use to estimate transition probabilities of the Markov model by comparing simulation results to benchmark values found in published literature. Results. In a comparison of CDI control strategies implemented individually, routine bleach disinfection of CDI-positive patient rooms provides the largest reduction in nosocomial asymptomatic colonization (21.8%) and nosocomial CDIs (42.8%). Additionally, vancomycin treatment provides the largest reduction in relapse CDIs (41.9%), CDI-related mortalities (68.5%), and total patient length of stay (21.6%). Conclusion. We develop a generalized ABM for CDI control that can be customized and further expanded to specific institutions and/or scenarios. Additionally, we estimate transition probabilities for a Markov model of natural CDI progression in a patient through calibration. Key words: Clostridium difficile; simulation methods; agent-based simulation; infectious disease control; hospital-acquired infections. (Med Decis Making 2015; 35:211-229) C lostridium difficile infection (CDI) is the leading infectious cause of health care-associated diarrhea. CDI affects more than 500,000 Americans every year and is responsible for nearly 20,000 deaths annually. There is strong evidence that the incidence and severity of CDI are increasing. [1] [2] [3] Mortality rates from CDI increased more than 400% between 2000 and 2004. 1 In some studies, CDI has surpassed methicillin-resistant Staphylococcus aureus (MRSA) as the most common hospitalacquired infection. 4 Recent guidelines from the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) discuss several strategies for reducing the transmission of C. difficile in a health care institution. 5 These include treatment with antibiotics for patients with CDI, environmental decontamination of rooms with bleach, increased health care worker (HCW) hand hygiene using soap and water, and contact isolation of diseased patients. However, control of CDI continues to be problematic. Adherence to contact isolation and hand hygiene proves to be challenging to achieve. 6 While several studies have investigated how these strategies individually affect C. difficile spread in small epidemic settings, 3, [7] [8] [9] to the best of our knowledge there is no systematic method to evaluate the combined effects of these control measures in endemic and large epidemic situations. Furthermore, many existing models often consider transmission of C. difficile without modeling the interactions among patients, visitors, and HCWs, thus ignoring important vectors of transmission and sources of variability. 10 The complexity of CDI outbreaks and the interactions among patients, visitors, and HCWs present a problem that makes it too difficult to analytically compute how recommended control strategies affect performance metrics such as total patient length of stay (LOS), prevalence of asymptomatic C. difficile colonization, CDI incidence, and CDI-related mortality. In this study, we develop a discrete-event agentbased simulation model (ABM) that can be used to determine the best CDI control strategies for a particular situation. An ABM is ideal for studying such a problem, because it can model the effects on transmission of C. difficile through agent interactions and the effect of CDI control strategies on agent behavior inside the system. The main objective of this study is to develop a core framework to model CDI transmission and control in a hospital. This simulation can then be improved upon to build more advanced and complex future models. Additionally, we develop a Markov model of the natural progression of CDI in a patient and estimate the transition probabilities through calibration.
METHODS

Overview of the ABM
We develop a discrete-event ABM that simulates C. difficile transmission and control in a general midsized hospital. An ABM is an extension of traditional discrete-event simulation in which the agents in the model have unique attributes and interact with each other. These interactions affect the simulation output and performance of the overall system. The ABM updates occur in discrete-time units, each equivalent to 5 simulated minutes. Our model hospital is compartmentalized into 10 wards with 10 rooms per ward and 2 beds per room. Diagrams of agent flow and environment construction are shown in Figure  1 . There are 3 agent types in our model: patients, HCWs, and visitors. Agents interact with each other and the environment, and these interactions serve as possible transmission routes for C. difficile.
We assume that HCWs and visitors are not susceptible to colonization or infection. However, they may become exposed to C. difficile through interactions and therefore spread C. difficile through the hospital. Hence, HCW and visitor agents have a binary descriptor indicating whether they are exposed to C. difficile. Describing C. difficile in patients is more complex, since we consider the possibility of asymptomatic colonization, CDI, and relapse CDI. Therefore, we use a Markov chain to model the C. difficile-related condition of each patient.
We use this ABM to evaluate 4 strategies that are commonly used to control the spread of CDI: a standard regimen of vancomycin, hereafter referred to as strategy (V), for treatment of CDI-positive patients; increased hand hygiene with soap and water for HCWs (H); contact isolation of diseased patients (I); and bleach disinfection of rooms that contain diseased patients (B). Additionally, we look at a mixed strategy (M) of all 4 individual strategies at the same time. These strategies affect the behavior of agents, the parameters relevant to C. difficile exposure and contamination, and, ultimately, the propagation of CDI in patients. Our ABM can be used to evaluate the impact of applying each strategy individually or a combination of strategies.
Agents and the Environment
Our model consists of 3 agent types: patients, HCWs, and visitors. Agents can interact with each other and the hospital environment, which is divided into wards consisting of patient rooms and a ward common area. The rooms and the common areas of each ward have a binary descriptor of C. difficile exposure: They either are free of C. difficile or are contaminated and thus risk exposing agents.
Patients arrive to the hospital following a Poisson process with arrival rate specified by historical data and are then assigned to a room. Each patient has several descriptive attributes including a unique patient ID number, age, LOS, remaining stay, designated ward, room assignment, bed assignment, CDI-related state, and exposure level. A patient is provided service for a lognormal distributed period of time and then discharged.
The HCW agents are assigned to specific wards and work in 12-hour shifts. There are 15 HCWs per ward, and each HCW services a set of patient rooms. Each HCW makes rounds visiting patients in the ward. Once a service round is completed, an HCW either can return to the ward common area to wait until the next time he or she tends to patients or can temporarily visit another ward then return at a later time. HCWs have a binary attribute that indicates whether the HCW has been exposed to C. difficile.
At the beginning of each day, a Bernoulli trial determines whether a patient receives visitors on that day. A patient may receive between 0 and 3 visitors at a time. C. difficile exposure for visitors works in the same fashion as HCWs. Visitors exposed to C. difficile can contribute to the transmission of C. difficile between patient rooms, in common areas, and through interactions with the patient they are visiting. While in the hospital, a visitor can either visit a patient in his or her room or wait in the ward's common area. We assume that patients in shared rooms can receive visitors and HCWs concurrently, and visitors and HCWs can be in a patient room at the same time.
Interactions
Interactions among the agents and interactions with the environment, such as rooms and ward common areas, are the primary modes through which C. difficile spreads. During an interaction, a Bernoulli trial is used to determine whether exposure to C. difficile occurs. The probability of exposure depends on the interaction type and is estimated from C. difficile contamination studies and expert opinion ( Table 1) . A patient can become exposed to C. difficile after interacting with an exposed HCW, visitor, or contagious patient with probability p ep , p ev , or p pe , respectively. After remaining in a contaminated room for 6 hours, a patient can become exposed to C. difficile with probability p env . Similarly, an HCW can become exposed to C. difficile by interacting with an exposed patient, with probability p eh , or being in a contaminated room, with probability p env . Finally, a visitor can become exposed to C. difficile after being in a contaminated room with probability p env , or interacting with a contagious patient, with probability p ep . 
Markov Model
Each patient agent has a dynamic C. difficilerelated status that is modeled as a discrete-time Markov chain. For simplicity and ease of computation, we assume that this Markov chain is updated every 6 hours of simulation time. The states of the Markov chain are described by a modified version of the natural history model proposed by Otten and others. 11 Namely, we use the following states to represent the C. difficile-related status of a patient: Susceptible (S), Exposed (E), Colonized (C), Diseased (D), Cleared (CL), Clinically Resolved Colonized (CR), Relapse Diseased (R), Dead (X), and Not Susceptible (NS). A patient in the Susceptible (S) state can develop CDI or asymptomatic colonization after exposure to C. difficile. If a patient is exposed to C. difficile after an interaction with a contagious patient, or another exposed agent, he or she will transition to the Exposed (E) state. The Exposed (E) state represents a patient who is exposed to C. difficile through interactions within the past 6 hours. Such a state is particularly useful for examining the effects of interactions among agents. A patient in the Colonized (C) state is asymptomatically colonized with C. difficile and can put others at risk for exposure. A patient in the Diseased (D) state has been diagnosed with active CDI and can expose other patients, HCWs, and visitors to C. difficile. A patient in the Cleared (CL) state once had an infection or colonization but is now recovered and is no longer contagious. A patient in the Clinically Resolved Colonized (CR) state once had CDI, but the symptoms have subsided despite the patient still having colonization of C. difficile.
Similarly, a patient in the Relapse Diseased (R) state once had CDI but is experiencing a recurrence of the previous CDI. A patient in the Dead (X) state has died due to CDI-related complications. Finally, a patient in the Not Susceptible (NS) state cannot develop colonization or CDI during his or her stay; that is, such patients do not fall into risk categories for CDI or colonization. Figure 2 shows the states and possible transitions of the Markov model.
CDI Control Strategies
Using several studies, we estimate strategy (V) as being effective in resolving CDI in 79.3% of CDI cases without relapse. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Due to the increased severity of CDI and the increased number of patients who meet requirements for vancomycin rather than other antibiotics, such as metronidazole, we consider vancomycin as the primary treatment. Other treatment methods such as metronidazole or fidaxomicin can be included in future iterations of the model, and we may estimate the proportion of CDI-positive patients who receive each treatment. Metronidazole is shown to be as less effective than vancomycin in treating CDI. 16, 22, 23 While fidaxomicin has been shown to be less effective than vancomycin at treating the hypervirulent NAP1 strain, it has been shown to be more effective at treating non-NAP1 CDI. [24] [25] [26] We assume that 100% of CDI patients will receive oral vancomycin treatment when the strategy is used and the diagnosis of CDI is 100% accurate. Hence, we do not consider any consequences of incorrectly treating patients without CDI. We make this assumption based on the current availability of highly accurate algorithms to detect CDI. Sharp and others 27 demonstrated that the use of the C. Diff Quik Chek Complete assay, which tests for both glutamate dehydrogenase and toxin A/B, followed by a randomaccess polymerase chain reaction test for discrepant results from the C. Diff Quik Chek Complete, results in high sensitivity (100%; 95% confidence interval [CI] 89.6%-100%) and high specificity (99.6%; 95% CI 97.3%-99.9%).
Strategy (H) requires all HCWs to thoroughly wash their hands for 25 seconds with soap and water. We use a hand hygiene adherence of 48%, as reported by Pittet and others, 28 who conducted one of the largest studies on hand hygiene in a hospital. We assume that each hand hygiene action removes C. difficile from the HCW's hands between taking care of patients. 4, 10 If increased hand hygiene measures are not enacted, HCWs may use alternative hand sanitation methods such as alcohol-based hand gel, which are shown to not effectively eliminate C. difficile contamination. 9 Strategy (B) involves the disinfection of rooms that have diseased patients every 24 hours and assumes 100% adherence to bleach disinfection when used. Last, strategy (I) entails the isolation of a diseased patient, who is placed in his or her own room and does not interact with other patients, and HCWs must wear protective gowns and gloves before entering the room. We assume 62% adherence to proper HCW gowning as indicated by Muto and others. 29 If there is insufficient room capacity, the patient is not isolated. We run 6 different strategies for comparison: no intervention strategy (N); the 4 individual strategies (V), (H), (I), (B); and the mixed strategy (M).
Input Parameters
There are 3 main sources for our data. The first source is aggregate patient data from the Wisconsin Hospital Association (WHA). The second is published papers from medical and epidemiological literature pertaining to CDI. The third data source consists of published statistics and guidelines from organizations such as the Centers for Disease Control and Prevention (CDC) and the American Hospital Association (AHA).
The WHA dataset consists of patient admissions to all health care institutions across the state of Wisconsin from 2007 to 2010. We use this dataset to estimate patient LOS, proportion of arrivals, patient age distribution, and susceptibility to CDI. We use published studies on C. difficile spread and control to estimate essential model parameters of C. difficile control strategies such as the duration of vancomycin treatment and the efficacy of bleach disinfection. A full list of input parameters is presented in Table 1 . Additionally, we use published literature to estimate outcome measures such as percentage of colonized patient population, mortality rates, and infection rates, all of which are used as calibration constraints for generating the transition probabilities of the Markov model as explained below. We use the AHA 2010 Fast Fact report to estimate the arrival rate of 17.55 patients per day. We initialize our model with a patient population equal to the average number of patients in the hospital at a given time.
Drawing on the WHA data, we assume patient LOS to be lognormally distributed ( Figure 3 ) and age to be normally distributed. We calculate the percentage of elderly patients, that is, patients over the age of 65, and consider all these patients to be susceptible to CDI. Therefore, we estimate the proportion of all patients who are susceptible to CDI during their stay to be 30.18%. We assume that HCW service times and visitor services times are exponentially distributed. All other parameters for which distribution data were not readily available are modeled as triangularly distributed with minimums and maximums of 75% and 125% of the mean (mode) values.
Calibration of the Markov Model
We use a discrete-time Markov chain to represent the natural progression of CDI in a patient. There are no available data to estimate the state transition probabilities directly, so for this purpose we use a method known as calibration, which is implemented as follows. First, we partition each transition probability p i,j into discretized values using an initial step size. This creates many different instances of P, denoted by P x , whose entries, denoted p i,j,x , are defined as the probability of a patient in state i transitioning to state j in 6 hours . For each P x , we impose constraints on the entries of n-step transition probability matrix, P x n , which are derived from the WHA dataset and long-term probabilities from published literature. We classify instances of P x that satisfy the constraints listed in Table 2 as feasible and instances of P x that fail to satisfy the constraints as infeasible. This generates a large set of feasible matrices denoted by P. Then, we randomly sample 2000 matrices from P into a new set P# and run 100 independent replications of the simulation for every P x in P#. Next, we examine the ABM output and accept the instances of P x whose benchmark values are within the lower and upper bound values obtained from the literature. 20, 21, [33] [34] [35] 37 We reject an instance P x if any of the 4 benchmark values lies outside of the lower or upper bounds. We then calculate the mean percentage error (MPE) for each benchmark statistic t and for each P x by comparing simulated results in each replication m, denoted yˆt ,x,m , with the benchmark values, denoted by y t , that are derived from published literature. We define the MPE of benchmark t pertaining to a probability matrix P x as MPEðP X Þ t 5
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We use AMPE to avoid biasing the calibration on the benchmark values with the largest magnitude. We define P TOP10 as the set of 10 instances of P x with the smallest AMPE value. P TOP10 is then used to run the simulation scenarios for the final results, and the larger set of feasible matrices P# is used to explore the effects of error in the estimates for the Markov model transition probabilities.
Verification and Validation
We use the definitions of verification and validation as presented by the renowned simulation textbook, Simulation Modeling & Analysis, by Law, who describes verification as ''determining that a simulation computer program performs as intended, i.e. debugging the computer program'' and validation as ''concerned with determining whether the conceptual simulation model (as opposed to the computer program) is an accurate representation of the system under study.'' 38(p299) In another paper on verification and validation, Kleijnen 39 outlines commonly used techniques for verification and validation.
Our simulation model is written in Java using the Eclipse IDE. For verification, agent logic is well documented and compartmentalized by agent type. Additionally, we perform tracing of agents via simulation output and using the Eclipse IDE debugger. Our tracing method follows randomly selected agents of each type through their stay in the hospital and checks whether the behavior of simulated agents matches the intended agent logic, which is mapped in Figure 4 .
Validation of the simulation model occurs in 5 segments: face validation, Markov model calibration results, calibration robustness, cross-validation, and sensitivity analysis. In face validation, one of the authors, Dr. Nasia Safdar, a health care epidemiologist and infectious diseases-trained physician, provided expertise on C. difficile transmission and Probability a patient will develop CDI after being cleared Olson and others, 17 Teasley and others 16 P R,X . P D,X Probability of death when relapse diseased is greater than the probability of death in diseased state O'Neill and others 57
Note: The notation P i,j n denotes (i,j) th entry in the n-step transition probability matrix P, where i and j correspond to states in the Markov model. CDC = Centers for Disease Control and Prevention; CDI = Clostridium difficile infection. control. The agents, environment, methods of interaction, Markov model states, and parameters are also developed in conjunction with Dr. Safdar to ensure that the model is a sufficiently accurate representation of a real hospital, while making the necessary simplifying assumptions to create such a model. Calibration of the Markov model is a validation of the natural history model by minimizing the error between the model predictions and the 4 performance benchmarks. We also study the effects of error in the performance target values by performing simulation runs using randomly sampled P x s in the set of matrices accepted by the calibration bounds, P#.
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Cross-validation is performed by running various scenarios found in published literature on CDI control and comparing our simulation results to those reported in these studies. These performance metrics are not used in the development of the model or calibration of the natural disease progression Markov model. Sensitivity analysis is used to confirm that changes in the input parameters correspond with logical changes in the simulation results.
Cross-Validation to Published Literature
We compare the simulation results to expected total patient LOS using our assumptions about patient LOS from the WHA data and published literature on CDI. Estimates are used from Louie and others, 19 who report the mean vancomycin treatment duration as 10 days; Teasley and others, 16 who find that 15%-23% of patients recover naturally in 2-3 days without the use of antibiotics; and Barbut and Petit, 40 who find that CDI is responsible for an 8-to 21-day increase in diseased patient LOS. Using the incidence of CDI and relapse CDI from our simulation results, we can use the parameters from these aforementioned publications and calculate the expected LOS of the 6 strategies discussed previously and then compare these estimates with results from our simulation. The efficacy of CDI control strategies depends strongly on the susceptibility of patient populations, adherence to CDI control strategies, and treatment of patients. Unfortunately, many of these data are not available from the literature. Hence, validation through comparison to findings in published literature is, at best, limited. For this reason, we refrain from performing statistical tests for validation; however, we demonstrate the feasibility of our results by comparing simulation results of similar scenarios to published studies. For a comparison metric, we use the rate ratio, which is defined as the ratio of CDI incidence after intervention over the CDI incidence before intervention.
Sensitivity Analysis
We perform a deterministic 1-way sensitivity analysis where we examine the output and look for a significant change (i.e., .5%) in asymptomatic colonizations, CDIs, relapse CDIs, mortalities, and total patient LOS. We also perform probabilistic sensitivity analysis, where we use a Monte Carlo approach such that parameters that are triangular or uniformly distributed random will have their minimum-maximum ranges extended by 650% of their original values, and other parameters will have their attributes changed by 650%.
RESULTS
Markov Model Calibration
The matrices in P TOP10 produced the following calibration results: average colonization incidence of 9.17% (MPE COL = 0.576%), CDI incidence of 1.44% (MPE CDI = 3.64%), proportion of relapse CDI as 22.43% (MPE RD = 11.091%), CDI-related mortality at 8.53% (MPE MOR = 11.782%), and an AMPE of 6.77%. We use this P TOP10 in the simulation for output validation, performance of individual control strategies, and sensitivity analysis. We evaluate the robustness of our selection of P x s by randomly sampling 10 unique P x s from P# and evaluating the simulation output generated by using these matrices to represent the parameters that dictate the natural progression of C. difficile in a patient. We perform these runs for each of the 6 strategy scenarios-(N), (V), (H), (I), (B), and (M)-and summarize the results as the maximum deviations from the results across all strategy scenarios. We observe a maximum deviation of 13.3% for colonizations, 11.61% for CDIs, 3.03% for relapse CDIs, 8.46% for mortalities, and 1.73 days for total patient LOS. Table 3 contains the full results of this analysis and Table 4 shows the difference range of each non-zero transition probability p i,j that has been accepted by the calibration. The results demonstrate that the choice of P x in P# provides a similar magnitude and rank for the efficacy of each individual CDI control strategy, despite the differences in the values of the p i,j s. Therefore, we conclude that our calibration method is stable against error in the choice of calibration targets and can easily be modified to match new and dynamic strains of C. difficile. Figure 5 showcases the effects of each scenario, with 95% confidence intervals, on the incidence of asymptotic colonization, CDI, relapse CDI, CDIrelated mortality, and total patient LOS. As expected, the mixed strategy (M) results in the largest reduction for all performance metrics: 41.5%, 83.7%, 86.3%, 92.8%, and 21.7%, respectively. However, strategy (B) results in the largest reduction in asymptomatic colonizations and CDIs, while strategy (V) results in the largest reduction in total patient LOS, relapse CDIs, and CDI-related mortalities. The results for individual strategies on the aforementioned performance metrics in order of efficacy on CDI reduction: Strategy (B) reduces colonizations by 21.83%, CDIs by 42.84%, relapse CDIs by 41.90%, CDI-related mortalities by 43.68%, and LOS by 9.18%; strategy (V) reduces colonizations by 14.61%, CDIs by 29.09%, relapse CDIs by 41.9 3%, CDI-related mortalities by 68.50%, and LOS by 21.63%.
Performance of CDI Control Strategies
We also compare our simulation results to those found in the literature. First, we compare the results of our model using environmental bleach disinfection of CDI incidence. Safdar and others 41 find the bleach disinfection rate ratio to be 0.21 (95% CI 0.11-0.39). Mayfield and others 3 report a bleach disinfection rate ratio to be 0.37 (95% CI 0.14-0.74) for bone marrow transplant patients, but there was no change in CDI incidence in the neurosurgical intensive care unit and no change in CDI incidence (i.e., rate ratio = 1) for general medicine patients. In another study, Wilcox and others 42 find the bleach disinfection rate ratio to be 0.595 in one ward and notice an increase in CDI (i.e., rate ratio . 1) in another ward. Using the same adherence rate of 88% for hand hygiene as Safdar and others, 41 which was the only study that reported hand hygiene adherence, our simulation results in a bleach-disinfection rate ratio of 0.428 (95% CI 0.401-0.455). Many factors can be responsible for the wide range of results from these studies, such as adherence to other interventions, which was not always present in these studies. Dettonkoffer and others 43 call for more detailed studies study of disinfection routines to identify the dependent variables of bleach disinfection efficacy.
Next, we compare our simulation results with Apisarnthanarak and others, 44 who report a rate ratio of 0.5 through implementation of contact isolation, increased hand hygiene, and environmental bleach disinfection. Adherence rates were not available from the study. However, using average adherence rates from published literature, 28, 29 our model reports a rate ratio of 0.546 (95% CI 0.540-0.552) with these strategies enacted. To summarize, the outputs from our simulation appear to be within reasonable ranges found in published literature on CDI control. However, due to the complexity of CDI control strategies and the precise data required for validation, such comparisons should be taken as demonstrative.
Finally, we can compare published study estimates of patient LOS with output from our simulation. The expected LOS from published studies for our 6-strategy scenarios is as follows: strategy (N), 5.41 days; strategy (V), 4.25 days; strategy (I), 5.14 days; strategy (H), 5.19 days; strategy (B), 4.91 days; and strategy (M), 4.26 days. Comparatively, our simulation attains the following LOS values: strategy (N), 5.44 days (95% CI 5.37-5.51); strategy (V), 4.26 days (95% CI 4.23-4.29); strategy (I), 5.13 days (95% CI 5.07-5.20); strategy (H), 5.20 days (95% CI 5.13-5.27); strategy (B), 4.94 days (95% CI 4.88-4.99); and strategy (M), 4.26 days (95% CI 4. 23-4.29) . The proximity of the LOS results indicates valid flow logic for patients with and without CDI. These results suggest additional validity of the Markov model, namely in the transition probabilities that dictate the duration of CDI. 
Results for the Sensitivity Analysis
Changes in parameters that are correlated with a significant increase compared with the average scenario are mapped in Table 5 . As expected, an increased proportion of patients susceptible to or colonized with C. difficile results in an increased incidence of colonizations, CDI, relapse CDI, and mortality. Increasing the probability of environmental contamination and increasing the probability of patient-to-HCW exposure lead to increases in nosocomial colonization and CDI. However, increased exposure probability with visitors does not necessarily lead to significantly more CDIs. These results imply that environmental contamination and HCWs may serve as significant sources of C. difficile transmission in the hospital; however, visitors may play only a minor role. Additionally, longer LOS for patients produced more CDIs, which is likely due to extended opportunities for C. difficile exposure. Figure 6 shows the results of the probabilistic sensitivity analysis including the 95% CIs for colonization, CDI, mortality, relapse CDI, and total patient LOS for each scenario. Overall, while increased variability in input parameters leads to increases in CDI related outcomes, the trend of strategy efficacy remains consistent with the average results. Additionally, increased uncertainty in input parameters does not result in large variability in the number of CDIs and relapse CDIs when strategy (M) is implemented. This is likely due to strategy (M) eliminating most nosocomial CDI due to the effectiveness of combined strategies. 
DISCUSSION
In this study, we achieve 2 goals. First, we develop an ABM that models C. difficile spread and control in a hospital. Second, we use parameter estimates from clinical studies on CDI and our ABM to estimate transition probabilities for a Markov model that describes the natural progression of CDI in a patient. Together, these provide a framework for future development of more complex models that may help clinicians and infectious disease experts understand the dynamics of C. difficile transmission and the efficacy of individual CDI control strategies.
Few studies have used agent-based modeling for nosocomial infectious diseases. Ruben and others 45 also use an agent-based approach to study isolation and treatment policies for CDI. However, they use a simpler stochastic model for CDI progression in a patient, and details on any calibration or validation methods used in their model were not publicly available at the time this article was submitted. Barnes and others 46 present an agent-based model for MRSA transmission and control that also considers interactions between patients, visitors, and HCWs; common MRSA control strategies; and a stochastic model for MRSA acquisition. We use this model as a starting point in the development of our ABM and expand these methods with additional complexities. For example, Barnes and others do not evaluate the effectiveness of environmental disinfection or consider HCW interactions with other HCWs. Several other models study nosocomial infections using differential equations with an estimated basic reproduction number value for CDI transmission. However, an ABM can analyze the system dynamics and complexity of interactions in a hospital and give a detailed account of C. difficile spread, without uniform generalizations on transmissibility. When modeling the natural history of CDI in a patient, Lanzas and others 10 use a more compact disease state transition model and exclude distinct states for relapse colonized and diseased patients. We consider lowprobability events and relapse CDI patients as possible sources for CDI outbreaks, and hence we use a more complete transition model that includes the aforementioned relapse states. Furthermore, modeling interactions among agents allows us to evaluate the effects of individual infection control strategies, whereas evaluating adjustments to the parameters of closed-form expressions may not capture a sufficient level of detail for small-scale disease transmission dynamics.
Our model is not without its limitations. Several of our parameters are approximated from limited data. The admission rates for Colonized, Infected, or Not Susceptible patients are not explicitly available from our data or the literature; hence, we rely on age as the only determining factor for CDI susceptibility. The inclusion of relative risk for different patient conditions would provide insight into CDI spread in at-risk patients. However, limited data on disease progression for specific patient types make it difficult to calibrate the state transition probabilities of the Markov model for many different patient types. We also assume that the probability of exposure to C. difficile after interaction with a contagious patient is the same for both HCWs and visitors. The exact relationship between these probabilities is not known at this time since the available data on the transmission of C. difficile spores to HCWs from patients are limited. That is, we are unaware of any studies on C. difficile transmission to visitors.
Additionally, since there may be different ways that the ABM matches observed data, our calibration method may not be very precise due to the unavailability of explicit data, which may also explain the variation given in Table 3 . Furthermore, our model considers only a generalized strain of C. difficile.
That is, we do not consider the possibility of a patient with the hypervirulent NAP1 strain, which has been shown to result in increased severity and transmissibility. 47 We make this assumption due to the lack of control studies on the NAP1 strain for CDI and the availability of data on C. difficile over other strains. The incidence of relapse CDI for patients who do not receive antibiotic treatment is not well documented. Therefore, we assume that the chance of relapse for CDI patients without vancomycin is the same as for those who receive vancomycin. Moreover, the behavior of agents and hospital design in our model is simplistic. However, additional detail without explicit information would add uncertainty and increase the difficulty of validation. Cost of CDI control is not included in our model at this time, as the evaluation of costs would require additional analysis to determine accuracy of such cost estimates. In one study, the cost of vancomycin ranged from $71 to $143 per day depending on regimen. 48 However, many CDI control costs require further study of indirect costs, which require more complexities and detail in the ABM. For example, the cost of increased hand hygiene measures depends heavily on HCW type (i.e., physician, nurse, or ancillary) and time.
Using 2012 average nurse and physician salary information from the US Bureau of Labor Statistics (USBLS), we estimate the cost of increased hand hygiene measures between $0.23 and $0.62 per hand-washing episode. Bleach disinfection costs associated with environmental services personnel time are estimated between $3.08 and $4.11 per room using USBLS information. Furthermore, the cost of contact isolation ranges from $0.46 to $0.66 per protective gown, but the cost of reduced patient capacity due to contact isolation is unknown. Hence, we leave the topic of cost analysis to be addressed in future work.
We have developed the model with a level of detail that we believe appropriately captures interactions among agents, yet it is sufficiently generalized to avoid any major flaws in our assumptions or limitations from scarce data. Furthermore, we do not consider modeling environmental disinfection strategies beyond bleach since clinical data on the efficacy of newer technology such as hydrogen peroxide vapor and ultraviolet light disinfection are limited and these tools are not extensively used at this time. Since our model's primary focus is on horizontal transmission of C. difficile, we do not introduce additional complexity by adding antibiotic stewardship constraints.
This model serves as a framework for more complex models. Future iterations of the model will include multiple strains of CDI, additional antibiotic treatments (i.e., metronidazole and fidaxomicin), relative risk of CDI due to a patient's underlying condition, antibiotic stewardship, and the possibility of treating false-positive CDIs. Additionally, due to the large number of parameters required for such a model, we plan to conduct a large observational study, which is necessary to obtain the data needed to perform a more rigorous calibration and validation of the model.
